Who
Harold Edward Fleming
Director
Company insider
Files Form 4 as: Director, Sionna Therapeutics; Director, Upstream Bio; Director, CRISPR Therapeutics AG.
In numbers
- Trades disclosed
- 14
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 10 Jun 2021
- Last trade
- 17 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 18 Jun 2026 | SION Sionna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,340 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | SION Sionna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,340 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | UPB Upstream Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —17,096 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | UPB Upstream Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —17,096 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | SION Sionna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,959 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | UPB Upstream Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —17,096 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 10 Oct 2024filed 15 Oct 2024 | UPB Upstream Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —17,096 at $0.00 | filing |
| 30 May 2024filed 31 May 2024 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 8 Jun 2023filed 9 Jun 2023 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 9 Jun 2022filed 10 Jun 2022 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 10 Jun 2021filed 14 Jun 2021 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.